Polyvalency: A promising strategy for drug design
- 26 August 2008
- journal article
- review article
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 101 (3) , 429-434
Abstract
The simultaneous binding of multiple ligands on one entity to multiple receptors on another can result in an affinity that is significantly greater than that for the binding of a single ligand to a single receptor. This concept of “polyvalency” can be used to design molecules that are potent inhibitors of toxins and pathogens. We describe the design of potent polyvalent inhibitors that neutralize anthrax toxin in vivo as well as our attempts to elucidate the relationship between inhibitor structure and activity. We also highlight promising future avenues for research in polyvalent drug design. Biotechnol. Bioeng. 2008;101: 429–434.Keywords
This publication has 37 references indexed in Scilit:
- Polymer TherapeuticsScience, 2007
- Display technologies: Application for the discovery of drug and gene delivery agents☆Advanced Drug Delivery Reviews, 2006
- Polyvalent inhibitors of anthrax toxin that target host receptorsProceedings of the National Academy of Sciences, 2006
- Synthesis of Potent Inhibitors of Anthrax Toxin Based on Poly-l-Glutamic AcidBioconjugate Chemistry, 2006
- Current status and future potential of transdermal drug deliveryNature Reviews Drug Discovery, 2004
- AnthraxNew England Journal of Medicine, 1999
- Polyvalent Interactions in Biological Systems: Implications for Design and Use of Multivalent Ligands and InhibitorsAngewandte Chemie International Edition, 1998
- Adsorption-Freezing Transition for Random Heteropolymers near Disordered 2D Manifolds due to “Pattern Matching”Physical Review Letters, 1996
- In vitro selection of RNA molecules that bind specific ligandsNature, 1990
- Systematic Evolution of Ligands by Exponential Enrichment: RNA Ligands to Bacteriophage T4 DNA PolymeraseScience, 1990